Last reviewed · How we verify
Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination
* This trial is a three-armed, open label, random assignment trial. * The research subjects are patients who are first starting their treatment or patients who have failed with the metformin treatment and are changing their medication. They will be assigned to one of the following treatment groups: the glimepiride monotherapy treatment group, the alogliptin monotherapy treatment group, and the alogliptin - pioglitazone combination therapy treatment group * This trial is a prospective trial which will conduct surveys 6 times over the course of the 6 months in which each treatment group is administered drugs (Week -2, Baseline, Week 4, Week 12, Week 24, follow-up safety survey). * This trial is a multicenter clinical trial which will be conducted at more than 5 general hospital medical institutions in the vicinity of the capital.
Details
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | PHASE4 |
| Status | UNKNOWN |
| Enrolment | 99 |
| Start date | Thu Dec 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Type 2 Diabetes Mellitus
Interventions
- Glimepiride
- Alogliptin 25Mg Tab
- Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet